NCT06935929View on ClinicalTrials.gov

A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease

CompletedOBSERVATIONAL
Enrollment

839

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions
Crohn Disease
Interventions
BIOLOGICAL

Ustekinumab - Standard Dosage

Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous dose of 90 mg UST at week 8.Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.

Trial Locations (1)

325000

the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06935929 - A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease | Biotech Hunter | Biotech Hunter